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Abstract
Background: The optimal treatment for latent multiple-drug resistant tuberculosis infection remains unclear. In anticipation
of future clinical trials, we modeled the expected performance of six potential regimens for treatment of latent multiple-
drug resistant tuberculosis.
Methods: A computerized Markov model to analyze the total cost of treatment for six different regimens: Pyrazinamide/
ethambutol, moxifloxacin monotherapy, moxifloxacin/pyrazinamide, moxifloxacin/ethambutol, moxifloxacin/ethionamide,
and moxifloxacin/PA-824. Efficacy estimates were extrapolated from mouse models and examined over a wide range of
assumptions.
Results: In the base-case, moxifloxacin monotherapy was the lowest cost strategy, but moxifloxacin/ethambutol was cost-
effective at an incremental cost-effectiveness ratio of $21,252 per quality-adjusted life-year. Both pyrazinamide-containing
regimens were dominated due to their toxicity. A hypothetical regimen of low toxicity and even modest efficacy was cost-
effective compared to ‘‘no treatment.’’
Conclusion: In our model, moxifloxacin/ethambutol was the preferred treatment strategy under a wide range of
assumptions; pyrazinamide-containing regimens fared poorly because of high rates of toxicity. Although more data are
needed on efficacy of treatments for latent MDR-TB infection, data on toxicity and treatment discontinuation, which are
easier to obtain, could have a substantial impact on public health practice.
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Introduction
Although the incidence of multiple-drug resistant tuberculosis
(MDR-TB, defined as resistance to isoniazid plus rifampin) in
countries with developed market economies is low, MDR-TB
incidence is high in many parts of the world [1]. The relative ease
of travel between these countries and countries with low TB
incidence facilitates the spread of transmissible diseases such as
MDR-TB. Therefore, the development of strategies to contain the
spread of MDR-TB is important not only for the developing world
but for countries with low MDR-TB incidence as well.
One such strategy is the prevention of active MDR-TB through
effective treatment during the latent phase of TB infection (LTBI).
Unfortunately, no treatment regimens for latent MDR-TB
infection have been tested in a randomized, controlled human
trial [2]. Based on animal models, case series, and expert opinion,
two preventive regimens are currently recommended by the U.S.
Centers for Disease Control and Prevention (CDC): Pyrazinamide
plus ethambutol or pyrazinamide plus a fluoroquinolone (such as
moxifloxacin), each for 6–12 months [3]. However, both regimens
have high rates of toxicity [4–7]. For immunocompetent
individuals, careful follow-up without treatment is also considered
a reasonable option. Therefore, the question of how to treat latent
MDR-TB infection (MDR-LTBI) – or even whether to treat it –
remains controversial.
Part of the solution may be found in new drugs currently in
development for the treatment of active TB. One of these drugs,
PA-824, has excellent sterilizing activity [8] and would therefore
be expected to have utility in the treatment of LTBI. Furthermore,
because of its novel mechanisms of action [9], it has activity
against MDR-TB [10]. The role of this and other new drugs in
treating latent MDR-TB infection is an area of much interest.
To help answer these questions about current and future
treatmentoflatent MDR-TBinfection,Nuermbergerandcolleagues
employed a murine model of arrested TB to compare several
different regimens for the treatment of MDR-LTB [11]. Although
the mouse model is an imperfect representation of human LTBI, the
model has successfully identified two regimens for treating drug-
susceptible LTBI, rifampin plus pyrazinamide and isoniazid plus
rifapentine, which have proven efficacious in clinical trials [12–14].
Anticipating clinical trials based on similar murine models, we
sought to define the key parameters that would make a future
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parameters and the impact of the uncertainty underlying their
estimates will be important for designing clinical trials to test
potential regimens. Therefore, we designed a mathematical model
to compare the expected performance of six potential regimens
over a range of clinically plausible estimates to provide useful
information to public health practitioners in the treatment of latent
MDR-TB infection.
Materials and Methods
Using TreeAge Pro (release 1.0.2, 2009, TreeAge Software,
Inc., Williamstown, MA), we created a Markov model [15]
(Figure 1) of a hypothetical exposure of MDR-TB in a cohort of
individuals otherwise at low risk for TB. We compared six different
treatment regimens (plus a strategy of ‘‘no treatment’’):
1. Pyrazinamide 1,500 mg plus ethambutol 1,600 mg (ZEmb)
2. Moxifloxacin 400 mg monotherapy (M)
3. Moxifloxacin 400 mg plus pyrazinamide 1,500 mg (MZ)
4. Moxifloxacin 400 mg plus ethambutol 1,600 mg (MEmb)
5. Moxifloxacin 400 mg plus ethionamide 1,000 mg (MEth)
6. Moxifloxacin 400 mg plus PA-824 400 mg (MP)
7. No treatment
Infecting MDR organisms were assumed to be susceptible to all
drugs in the model.
To account for excess cost associated with treating individuals
testing falsely positive on available diagnostic tests, we assumed
that only a portion of the cohort became infected after exposure
(10% in the base-case, see below). A test for LTBI was then
applied, the sensitivity and specificity of which was varied to
simulate either tuberculin skin testing (TST) or interferon gamma
release assay testing. Individuals were either treated or not treated
based on the results of this test. Because individuals in the cohort
were assumed to be at low risk for prior TB infection, all active
cases were assumed to be multi-drug resistant.
The model was analyzed from the societal perspective using
cycles of one month duration. Payoffs were calculated for costs and
quality-adjusted life-years (QALY) based on U.S. data. Costs and
life-years were discounted at 3%. Incremental cost-effectiveness
ratios (ICER) were calculated for each regimen, with a willingness-
to-pay threshold of $50,000 per QALY chosen to determine cost-
effectiveness. All costs were based on U.S. public health pricing
and were converted to 2009 U.S. dollars using the Gross Domestic
Product deflator [16].
Transition probabilities
The initial probabilities and utility adjustments used in the
model are shown in Tables 1 and 2.
To determine the probability of infection after exposure, we
started with North Carolina TB surveillance data (Aggregate
Reports for Tuberculosis Program Evaluation, unpublished). For
2009, 16% of close contacts to active cases had a positive TST.
However, because over 4% of individuals in the U.S. have a
positive TST at baseline [28], we assumed a probability of new
infection of 10%.
For recently-infected contacts to an active case of drug-
susceptible TB, the lifetime risk of progressing from LTBI to
active TB is estimated at 7%, with approximately half of the
disease occurring in the first two years [3,17]. However, compared
with fully-susceptible strains, drug-resistant strains appear to be
somewhat less virulent [29–32], generating about half the number
of secondary cases [20]. Because contacts to MDR-TB appear to
have equal rates of TST positivity [33], the evidence suggests that
MDR strains are just as infectious as drug susceptible strains, but
patients infected with MDR strains are less likely to activate.
Therefore, we adjusted our base-case estimate of lifetime risk
down to 4%, while exploring higher rates of activation in the
sensitivity analysis.
Members of the MDR-TB-exposed cohort who developed
active TB were assumed to infect other individuals, some of whom
would eventually develop active TB. A previously-described model
of drug-susceptible TB suggests that each case of active TB in the
U.S. will result in approximately 1.2 additional future cases
through successive transmission distributed over 44 years [21], but
due to the lower number of secondary cases generated by MDR
strains (as mentioned above), we adjusted the base-case estimate to
0.6. These assumptions were explored in sensitivity analyses.
Assumptions
We extrapolated initial efficacy estimates from Nuermberger
and colleagues’ data on murine splenic culture sterilization. In
their experiments, the six drug regimens and a control regimen of
isoniazid were each given to experimentally-infected mice for six
months, after which splenic cultures were obtained. To obtain our
estimates, we ranked the regimens in order of their efficacy in the
mice, and then divided the regimens into quintiles. Using isoniazid
as a reference, we extrapolated the efficacy of each quintile,
assuming that all regimens had at least partial efficacy. The
estimates used in the model are listed in Table 1 and explored in
sensitivity analyses.
We assumed that the risk of treatment-limiting adverse events
for moxifloxacin was the same as for other quinolones. Under this
assumption, data on the tolerability of pyrazinamide/ethambutol
and moxifloxacin/pyrazinamide was taken directly from available
literature [4–7,27]. Data suggest that there is little additional
toxicity when fluoroquinolones are given as part of a larger TB
treatment regimen [19,34] and fluoroquinolone monotherapy
appears to be relatively well-tolerated [35], so we assumed that
moxifloxacin monotherapy has a toxicity profile similar to
isoniazid. No data for tolerability of moxifloxacin/ethambutol or
moxifloxacin/ethionamide exist, so we used toxicity rates
published for ethambutol and ethionamide in active MDR-TB
to estimate their additional toxicity [19]. Likewise, no data on the
administration of PA-824 beyond seven weeks has been published
[36], but we assumed in our base-case analysis that it had a similar
tolerability profile to moxifloxacin monotherapy.
Although no cases series for treatment of MDR-LTBI have
reported toxicity resulting in death, numbers are quite low. Based
on data from isoniazid monotherapy, we assumed that 1% patients
who experience treatment-limited toxicity would require hospital-
ization and that of those patients, 1% would die [18]. These
toxicity estimates are shown in Table 2.
Case series suggest that the mortality of active MDR-TB is
approximately 12% [19]. We assumed that half of these patients
would die within the first month of treatment of active disease
[37], with the balance distributed throughout the remainder of
treatment. The risk of non-TB death was taken from age-specific
mortality tables [38].
In case series of pyrazinamide-containing regimens, some
individuals discontinued medications prematurely but did not
experience serious side effects. Although low numbers preclude an
accurate estimate, the proportion of patients in these series who
stopped due to non-adherence appears to be similar to non-
completion rates reported in studies of isoniazid. Therefore, we
assumed that 80% of individuals not experiencing toxicity would
Strategies for Treating Latent MDR-TB
PLoS ONE | www.plosone.org 2 January 2012 | Volume 7 | Issue 1 | e30194Figure 1. Schematic of decision tree. A. Primary tree showing decision point between regimens and probability of a positive or negative test
given presence or absence of infection. B. Positive test subtree. Individuals begin ‘‘on treatment’’ then move to ‘‘off treatment’’ due to toxicity, non-
adherence, or treatment completion. Patients in ‘‘off treatment’’ can develop active disease and move to ‘‘TB treatment;’’ after treatment for active
disease, they move to ‘‘prior TB.’’ Age-related mortality and death from TB or toxicity is also included. The negative test subtree is similar to the
positive test subtree without the ‘‘on treatment’’ branch. Abbreviations: MZ=moxifloxacin+pyrazinamide, ZEmb=pyrazinamide+ethambutol,
MEth=Moxifloxacin+ethionamide, MP=moxifloxacin+PA-824, M=moxifloxacin monotherapy.
doi:10.1371/journal.pone.0030194.g001
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six months [24,25]. Therefore, 5% of individuals would discon-
tinue therapy each month for the first four months and 8% would
discontinue therapy each month thereafter (Table 2). We
assumed that these individuals were lost to follow up and did
not restart treatment [25].
Because some health states in our model are associated with
lower quality of life, we included utility adjustments to life-years for
patient transitioning through these health states (shown in
Table 1). Data for these adjustments are limited [23], so we
tested a wide range of assumptions in sensitivity analyses.
Cost estimates
Costs for treatment of latent infection are shown in Table 3;
because we assumed that all patients within each group were
tested, costs of testing were not included. Drug prices were taken
from current North Carolina public health pharmacy costs; PA-
824 was assumed to cost the same as moxifloxacin. It was assumed
that all patients on a pyrazinamide-containing regimen and 40%
of patients on other regimens would receive monthly laboratory
monitoring. Costs associated with severe toxicity and hospitaliza-
tion were incurred only for patients experiencing those events.
Costs for treatment of active disease are shown in Table 4.W e
assumed that 75% of patients with active disease would be
hospitalized, following which patients would receive directly-
observed therapy (standard of care for patients with MDR-TB)
every day for a total of 18 months. We assumed patients would
come to the clinic for intramuscular injections during the first four
months of therapy but would receive directly-observed therapy
(DOT) in the field thereafter.
Table 1. Model parameters and utility adjustments, point
estimates and ranges for sensitivity analyses.
Variable Estimate Range Source
Lifetime risk of TB 0.04 0.04–0.06 [3,17]
Proportion of patients hospitalized
for toxicity
0.1 0.05–0.2 [18]
Proportion of hospitalized patients
dying from drug toxicity
0.01 0–0.03 [18]
Probability of death from TB 0.12 0–0.12 [19]
Number of secondary cases
per active case
0.4 0–1.2 [20,21]
Initial probability of infection 0.1 0–1 (assumed)
Test characteristics for detection
of latent TB
Sensitivity 0.78 0.63–0.82 [22]
Specificity 0.95 0.59–0.99 [22]
Quality of life adjustments (life-years)
LTBI treatment 0.97 0.85–0.97 [23]
Treatment-limiting toxicity 0.75 0.65–085 (assumed)
Hospitalization 0.5 0.40–0.60 (assumed)
Treatment of active TB 0.90 0.64–0.93 [23]
Prior TB 0.95 0.85–1 (assumed)
doi:10.1371/journal.pone.0030194.t001
Table 2. Base-case estimates for protection, adherence, and
toxicity for the six regimens and ranges for sensitivity
analyses.
Variable Estimate Range Source
Risk reduction from treatment
Pyrazinamide+ethambutol (ZEmb) 0.62 0–1 [11]
Moxifloxacin+pyrazinamide (MZ) 0.90 0–1 [11]
Moxifloxacin monotherapy (M) 0.62 0–1 [11]
Moxifloxacin+ethambutol (MEmb) 0.76 0–1 [11]
Moxifloxacin+ethionamide (MEth) 0.69 0–1 [11]
Moxifloxacin+PA-824 (MP) 0.98 0–1 [11]
Non-adherence per month (no toxicity)
0–4 months 0.05 0–1 [4,5,24–26]
5–6 months 0.08 0–1
Probability of stopping from toxicity
Pyrazinamide+ethambutol (ZEmb) 0.58 0–1 [7]
Moxifloxacin+pyrazinamide (MZ) 0.67 0–1 [4–6,27]
Moxifloxacin monotherapy (M) 0.014 0–1 (assumed)
Moxifloxacin+ethambutol (MEmb) 0.04 0–1 (assumed)
Moxifloxacin+ethionamide (MEth) 0.07 0–1 [19]
Moxifloxacin+PA-824 (MP) 0.04 0–1 (assumed)
doi:10.1371/journal.pone.0030194.t002
Table 3. Costs for treating latent MDR-TB infection, point
estimates and ranges for sensitivity analyses.
Estimate Range Reference
Monthly visit costs
Nursing visit ($31.97/hr) $17.41 [39]
Labs
* $7.70 [39]
Physician visit
** $11.90 [39]
Total visit cost $37.01 $27.76–46.26
Drug costs
Moxifloxacin 400 mg $3.42 ***
Pyrazinamide 500 mg $0.43 ***
Ethambutol 400 mg $0.46 ***
Ethionamide 250 mg $2.10 ***
PA-824 $3.42 (assumed)
Total monthly costs
Pyrazinamide+ethambutol $129.41
Moxifloxacin+pyrazinamide $190.61
Moxifloxacin monotherapy $140.12
Moxifloxacin+Ethambutol $181.52
Moxifloxacin+Ethionamide $403.91
Moxifloxacin+PA-824 $345.32
Severe toxicity costs
Lab monitoring $161.60 [39]
Hospitalization (7 days) $5428.78 $4,071–$6,786 [40]
*Average cost of routine monitoring and evaluation for mild toxicity assuming
40% of patients will require monthly monitoring of hepatic enzymes (100% for
patients on pyrazinamide) and 1.4% will have toxicity severe enough to require a
physician evaluation but that does not limit treatment.
**Medicare cost assumed for 15 minutes of physician time for 40% of patients.
***North Carolina Public Health Pharmacy Data.
doi:10.1371/journal.pone.0030194.t003
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To account for parameter uncertainty, we conducted multiple
sensitivity analyses by varying the parameter estimates over the
specifiedranges.Whereavailable,weusedrangesforinputsbasedon
publishedliterature.Forcosts,we determined therangebyaddingor
subtracting 25% from the base case estimate. One-, two-, and three-
waysensitivityanalyseswereperformedasappropriate.Ourprimary
analysisfocusedonthesearchforthresholdsthatcoulddefineclinical
trial parameters, primarily efficacy and toxicity for each regimen, so
estimates for these inputs were tested over a wide range.
Results
The point estimates for costs, QALY’s, and ICER’s for each
regimen are shown in Tables 5 and 6, and Figure 2. In the base
case, all regimens were associated with greater quality-adjusted life
expectancy than the ‘‘no treatment’’ strategy. Furthermore, the
‘‘no treatment’’ strategy was dominated by (more expensive and
less effective than) moxifloxacin monotherapy.
Moxifloxacin monotherapy was the lowest cost regimen (due to
relatively low treatment costs, efficacy, and tolerability), but
moxifloxacin/ethambutol was more effective than this regimen at
a cost of $21,252 per QALY. Moxifloxacin/PA-824 was the most
effective regimen, though at an ICER of $57,771 per QALY
(compared with moxifloxacin/ethambutol), given our cost-effec-
tiveness threshold of $50,000 per QALY it would not be
considered a good use of resources. All other regimens were
dominated by moxifloxacin/ethambutol.
Sensitivity Analysis
Both pyrazinamide-containing regimens (moxifloxacin/pyrazin-
amide and pyrazinamide/plus ethambutol) were substantially less
effective than the other drug regimens modeled. Because of the
extremely high rates of toxicity for these two regimens, there was
no threshold for efficacy of either regimen above which either one
became a cost-effective strategy compared with available alterna-
tives. Additionally, they would only become cost-effective
compared to moxifloxacin/ethambutol at extremely low estimates
for the protection afforded by moxifloxacin/ethambutol combi-
nation (,10%).
The overall effectiveness of a regimen was determined primarily
by its toxicity/tolerability and its efficacy. Figure 3 shows a
strategy graph comparing the moxifloxacin plus ethambutol
strategy with the ‘‘no treatment’’ strategies at various drug costs.
At base-case estimates for drug costs ($182 per month, equivalent
to the cost of moxifloxacin plus ethambutol), the drug regimen
could have a relatively low efficacy and still be cost-effective when
compared to ‘‘no treatment’’ as long as treatment-limiting toxicity
is also low. Figure 3 also shows thresholds for cost-effectiveness
for the least expensive and most expensive drug regimens ($129
and $404 per month, respectively). As an example, the dotted lines
on Figure 3 show the point estimates for toxicity and efficacy for
moxifloxacin/ethambutol, which would be cost-effective even if
the regimen costs were over $404 per month. However, a
hypothetical regimen with 60% efficacy and a severe toxicity rate
of 50% would only be cost-effective if the cost of treatment were
$129 per month (and not at $404 per month).
Table 4. Costs for treating active MDR-TB, point estimates and ranges for sensitivity analyses.
Units Cost/unit Total cost Range Reference
Diagnosis $456.84 $342–571 [41]
Inpatient treatment $24,853 $5,278–73,572 [42]
DOT costs [41,43]
Outreach worker (per hour) 1 $17.10 $17.10
Patient time (per hour) 0.1 $15.16 $1.52
Driving (miles) 10 $0.55 $5.50
Total DOT cost $24.12 $18–30
Outpatient (per month, months 1–4)
Drug 20 $30.55 $611.00 Table 2
DOT 0 $22.32 0
Nursing (30 minutes) 10 $32.62 $326.20 [41]
Pt. time per monthly visit 1.5 $15.16 $454.80 [41]
Pt. travel (10 miles @ $0.55/mile) 20 $110.00 $2,200.00 [41]
Monitoring
* 4 $90.32 $361.28 [41]
Total outpatient (months 1–4) $3,953.28 $2,964–4,941
Outpatient (per month, months 5–18)
Drug 20 $25.04 $500.80 Table 2
DOT 20 $24.12 $482.32
Nursing (30 minutes) 0.5 $32.62 $16.31 [41]
Pt. time per monthly visit 1.5 $15.16 $22.74 [41]
Monitoring* 1 $90.32 $36.13 [41]
Total outpatient treatment (mos. 5–18) $1,112.49 $834–1,390
Contact tracing/testing (90% of contacts screened) 5.2 $135.71 $635.14 $478–794 [43,44]
Total per case – 18 months therapy $51,220.22
doi:10.1371/journal.pone.0030194.t004
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but under base-case estimates for efficacy and tolerability,
moxifloxacin/PA-824 would be cost-effective compared to moxi-
floxacin/ethambutol at a cost per pill for PA-824 of $3.32 or less
(compared to the base-case $3.42). Results were not sensitive to
variations in the costs of toxicity or TB treatment over the
specified ranges.
Results were not sensitive to changes in overall adherence if the
adherence rates of all regimens (excluding discontinuation related
to toxicity) are similar. Pyrazinamide-containing regimens were
not cost-effective even if their adherence rates (not related to
toxicity) were 100%.
To account for the variable accuracy of different LTBI tests in
different populations, we performed sensitivity analysis on the test
characteristics. At a test specificity below 74 (base-case esti-
mate=95%), none of the drug treatment regimens were cost-
effective compared to the ‘‘no treatment’’ strategy. For test
specificity between 74–86%, moxifloxacin monotherapy is the
preferred strategy. No thresholds for sensitivity were found.
If the prevalence of infection is below 2%, the ‘‘no treatment’’
strategy is preferred over all treatment options. For prevalence
between2–4%,thepreferredstrategy is moxifloxacinmonotherapy.
If the lifetime risk of activation is increased to 6% (baseline
estimate=4%), both moxifloxacin/ethambutol and moxifloxacin
dominate the ‘‘no treatment’’ strategy. Furthermore, moxiflox-
acin/PA-824 becomes cost-effective compared to moxifloxacin/
ethambutol at a cost of $33,350 per QALY. Increasing the number
of secondary cases of active TB to 1.2 per active case in the cohort
(base case estimate=0.6) also resulted in both moxifloxacin/
ethambutol and moxifloxacin dominating the ‘‘no treatment’’
strategy.
The utility of prior TB (base-case estimate 0.95) had one
threshold at 0.91 below which moxifloxacin/PA-824 became the
preferred strategy. There were no other thresholds for utility
adjustment over the specified ranges.
Discussion
In our analysis, efficacy, toxicity, and cost were the key
parameters determining the overall cost effectiveness of the
different regimens. Specifically, the tradeoff between efficacy and
toxicity was a primary parameter, in that regimens with relatively
low efficacy could be cost-effective compared to ‘‘no treatment’’ if
they are well-tolerated.
Table 5. Lifetime costs and quality-adjusted life-years (QALY) for all regimens, efficacy predicted by murine model:
MP.MZ..MEmb.MEth=Isoniazid.M=ZEmb.
Strategy Cost
Incremental
cost
Effectiveness
(QALY)
Incremental
effectiveness ICER ($/QALY)
*
M $205.32 (ref) 22.68017 (ref)
No treatment $210.08 $4.75 22.67518 (0.00509) (Dominated)
MEmb $220.25 $14.93 22.68097 0.000702 $21,253
ZEmb $251.36 $31.10 22.67656 (0.00441) (Dominated)
MZ $271.85 $51.60 22.678698 (0.00399) (Dominated)
MP $301.74 $81.49 22.68238 0.00141 $57,771
MEth $368.60 $66.86 22.68029 (0.00209) (Dominated)
Regimens referenced to the lowest-cost strategy.
*Incremental cost-effectiveness ratios (ICERs) are calculated relative to next-lowest-effectiveness option.
Abbreviations: MZ=moxifloxacin+pyrazinamide, ZEmb=pyrazinamide+ethambutol, MEth=Moxifloxacin+ethionamide, MP=moxifloxacin+PA-824, M=moxifloxacin
monotherapy.
doi:10.1371/journal.pone.0030194.t005
Table 6. Lifetime costs and quality-adjusted life-years (QALY) for all regimens, efficacy predicted by murine model:
MP.MZ..MEmb.MEth=Isoniazid.M=ZEmb.
Strategy Cost Incremental Cost
1 Effectiveness (QALY)
Incremental
effectiveness
1 ICER ($/QALY)
1
No treatment $210.08 (ref) 22.67518 (ref)
ZEmb $251.36 $41.28 22.67656 0.001381 $29,891.72
MZ $271.85 $61.77 22.67698 0.001802 $34,280.37
M $205.33 ($4.75) 22.68026 0.005087 (Dominant)
MEth $368.60 $158.52 22.68029 0.005113 $31,003.29
MEmb $220.25 $10.18 22.68097 0.00579 $1,757.49
MP $301.74 $91.66 22.68238 0.0072 $12,730.82
Regimens referenced to a strategy of ‘‘no treatment’’ and ordered by increasing effectiveness.
1Incremental costs, effectiveness, and cost-effectiveness ratios are referenced to the strategy of ‘‘no treatment.’’
Abbreviations: MZ=moxifloxacin+pyrazinamide, ZEmb=pyrazinamide+ethambutol, MEth=Moxifloxacin+ethionamide, MP=moxifloxacin+PA-824, M=moxifloxacin
monotherapy.
doi:10.1371/journal.pone.0030194.t006
Strategies for Treating Latent MDR-TB
PLoS ONE | www.plosone.org 6 January 2012 | Volume 7 | Issue 1 | e30194In our base-case analyses, moxifloxacin monotherapy was the
lowest cost option, though moxifloxacin/ethambutol was a cost-
effective alternative. These strategies maintained superior cost-
effectiveness over a wide range of reasonable estimates for
adherence and toxicity. The standard regimens recommended
by the CDC, pyrazinamide/ethambutol and pyrazinamide/
Figure 2. Cost-effectiveness plot for six regimens plus the ‘‘no treatment’’ strategy. Superior regimens are lower in cost (toward the left)
and greater in efficacy (toward the top). Incremental cost-effectiveness ratios (ICERs) are shown for the two most effective regimens referenced to the
strategy of ‘‘no treatment.’’ Abbreviations: MZ=moxifloxacin/pyrazinamide, ZEmb=pyrazinamide/ethambutol, MEth=moxifloxacin/ethionamide,
MP=moxifloxacin/PA-824, M=moxifloxacin monotherapy. ICER=incremental cost-effectiveness ratio in dollars per quality-adjusted life-year.
doi:10.1371/journal.pone.0030194.g002
Figure 3. Strategy graph of efficacy vs. toxicity. Solid lines indicate thresholds (‘‘isoclines’’) for indifference given monthly drug costs of $129
(pyrazinamide/ethambutol), $181 (moxifloxacin/ethambutol), and $404 (moxifloxacin/ethionamide) per month. Shaded area indicates combinations
of toxicity and efficacy for which drug treatment is cost-effective compared to the ‘‘no treatment’’ strategy beneath each of these isoclines. Dotted
lines indicate the base-case estimates for efficacy and toxicity of moxifloxacin/ethambutol.
doi:10.1371/journal.pone.0030194.g003
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strategy, were substantially less effective than other regimens.
Our model is subject to several limitations. First, many of the
parameters in our study are currently unsupported by human
clinical trials. However, it was not our attempt to calculate the
precise cost-effectiveness for any of the regimens, but rather to
determine their relative cost-effectiveness over a range of parameter
estimates and to determine which uncertainties within the
parameter estimates had the greatest impact on our findings and
therefore should be prioritized in future research studies.
Next, our model assumes that the MDR-TB isolates are
susceptible to most of the second-line antituberculous agents,
particularly moxifloxacin. Fluoroquinolone-resistant strains are
relatively rare among MDR-TB isolates in the U.S. [45] but are
increasingly common worldwide [46,47]. Although these strains
limit the usefulness of our model’s most effective regimens outside
of the U.S., the results should still be applicable for U.S. TB
control programs or other areas where fluoroquinolone resistance
is low.
In addition, our analysis was restricted to a population of low-
risk individuals. In high-risk individuals, such as those with human
immunodeficiency virus infection, even a slight improvement in a
regimen’s overall effectiveness will prevent a large number of
additional cases, magnifying both the health and economic benefit
from treatment. In some cases, this additional cost savings may be
enough to compensate for a more expensive regimen [48].
Lastly, the results of our model are only applicable to settings
with the overall burden of TB is low, such as in most developed
economies. We implicitly assumed that no one became re-infected
after treatment for LTBI, so any setting where the probability of
re-infection is substantial would make all treatments appear less
effective [49].
In our analysis, incremental effectiveness was small. There are
two primary reasons for this finding. First, our hypothetical cohort
was limited to otherwise healthy individuals in a developed
economy (e.g., the United States), where mortality from TB is very
low, even for MDR-TB. More importantly, however, we modeled
exposure and testing in such a way that the majority of individuals
in the cohort were not infected and were therefore did not benefit
from any treatment. Elimination of this portion of the model
increases the incremental effectiveness of the regimens, but also
increases costs.
The cost of treating MDR-TB was estimated from local
practices and drug costs. Rajbhandary et. al. calculated much
higher total costs for treating active MDR-TB (an average of
$117,440 in 2011 U.S. dollars per case) [42]. However, much of
this higher cost is due to assumptions of greater loss of productivity
(including that due to death) than in our model. Furthermore,
their study did not describe drug resistance patterns for the
patients on which the cost data were based. In an attempt to be
conservative, we assumed a ‘‘best-case’’ scenario with limited drug
resistance and no requirement for surgery. If these higher
estimates were used, all drug regimens would appear much more
cost-effective in relation to the ‘‘no treatment’’ strategy.
Of note, analysis of the sensitivity and specificity of our TB
testing strategy suggests that the ‘‘no treatment’’ strategy would be
preferred in situations where the test specificity is low. In BCG-
immunized individuals, the specificity of the tuberculin skin test
(approximately 59% [22]) is below our study’s threshold for
specificity. Therefore, if testing is to be a prelude to treatment, in
BCG-vaccinated populations exposed to MDR-TB, a test with
higher expected specificity, such as an interferon gamma release
assay, would be preferred.
The results of our study are consistent with a prior decision
analysis by Stevens and colleagues, who compared a fluoroquin-
olone plus ethambutol against a strategy of ‘‘no treatment’’ in
HIV-uninfected healthcare workers [26] and found that this drug
combination was slightly superior to no therapy. However, they
did not consider other alternatives, nor did they consider the costs
associated with treating TB or secondary cases. Because these costs
are an important factor in determining the economic viability of a
regimen, their consideration greatly assists public health officials in
choosing among available options.
Although data for our assumptions regarding PA-824 are
limited, our model suggests it (or other new drugs) is worthy of
further study. Assuming a low level of toxicity, it would be
expected to be superior to either of the standard pyrazinamide-
containing regimens and would be cost-effective compared to the
other regimens if its drug costs are lower than estimated.
Clearly, more data are needed to determine the best treatment
for latent MDR-TB infection, but even in the absence of such
data, our study suggests two important conclusions. First, our
analysis shows that regimens need not be highly efficacious to be
clinically useful so long as they are well-tolerated. Therefore, in the
absence of new efficacy data, a relatively inexpensive study
focusing on toxicity and tolerability of either the moxifloxacin/
ethambutol or moxifloxacin/PA-824 combinations (or both)
would provide important information regarding the utility of
these regimens. Second, because toxicity and tolerability were such
important determinants of the overall efficacy of the regimens in
our model (and are of particular concern for preventive therapy in
general), both pyrazinamide-containing regimens performed
poorly. Therefore, we believe that the benefit of pyrazinamide-
containing regimens for the treatment of latent MDR-TB infection
be reconsidered in favor of regimens with better expected
tolerability, moxifloxacin monotherapy or moxifloxacin plus
ethambutol.
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